Recurrent Melanoma Completed Phase 3 Trials for DB01229 (Paclitaxel)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00110019Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment